BioNexus Gene Lab Corp. BGLC shares are trading higher Friday. The company uplisted its BGLC shares to the Nasdaq Capital Market with a public offering on Thursday.
What To Know:
BioNexus Gene Lab Corp.'s offering included 1.25 million shares priced at $4 per share, and the company expects proceeds from the offering will total $5 million. There is the possibility of more funds if underwriters exercise their 45-day rights to acquire an additional 187,500 shares at the public offering price.
BGLC shares are trading on very heavy volume and interest from retail investors. According to data from Benzinga Pro, more than 6 million shares have already been traded in the session, compared to the BGLC 100-day average of 51.94 thousand shares.
Related News: Why Trump-Related Digital World Acquisition Corp. Shares Are Soaring
BGLC Price Action: According to Benzinga Pro, BioNexus Gene Lab shares are trading 17% higher at $5.70 at the time of publication.
Image: TheDigitalArtist from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.